Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species

Lara Davis, Sophia Jeng, Matthew N. Svalina, Elaine Huang, Janét Pittsenbarger, Emma L. Cantor, Noah Berlow, Bernard Seguin, Atiya Mansoor, Shannon McWeeney, Charles Keller

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell cycle or immune) may prove more successful than targeting specific kinase or growth factor signaling pathways. Here, we establish a comparative oncology approach characterizing the most lethal osteosarcomas identified in a biorepository of tumors from three different species: human, mouse and canine. We describe the development of a genetically-engineered mouse model of osteosarcoma, establishment of primary cell cultures from fatal human tumors, and a biorepository of osteosarcoma surgical specimens from pet dogs. We analyzed the DNA mutations, differential RNA expression and in vitro drug sensitivity from two phenotypically-distinct cohorts: tumors with a highly aggressive biology resulting in death from rapidly progressive, refractory metastatic disease, and tumors with a non-aggressive, curable phenotype. We identified ARK5 (AMPK-Related Protein Kinase 5, also referred to as NUAK Family Kinase 1) as a novel metabolic target present in all species, and independent analyses confirmed glucose metabolism as the most significantly aberrant cellular signaling pathway in a model system for highly metastatic tumors. Pathway integration analysis identified Polo Like Kinase 1 (PLK1)-mediated checkpoint adaptation as critical to the survival of a distinctly aggressive osteosarcoma. The tumor-associated macrophage cytokine CCL18 (C-C Motif Chemokine Ligand 18) was significantly over-expressed in aggressive human osteosarcomas, and a clustering of mutations in the BAGE (B Melanoma Antigen) tumor antigen gene family was found. The theme of these features of high risk osteosarcoma is checkpoint adaptations, which may prove both prognostic and targetable.

Original languageEnglish (US)
Pages (from-to)76241-76256
Number of pages16
JournalOncotarget
Volume8
Issue number44
DOIs
StatePublished - 2017

Fingerprint

Osteosarcoma
Neoplasms
Phosphotransferases
Melanoma-Specific Antigens
CC Chemokines
Mutation
AMP-Activated Protein Kinases
Primary Cell Culture
Pets
Neoplasm Antigens
Protein Kinases
Cluster Analysis
Canidae
Intercellular Signaling Peptides and Proteins
Cell Cycle
Macrophages
Genome
Dogs
RNA
Cytokines

Keywords

  • Checkpoint adaptation
  • Comparative oncology
  • Metastases
  • Osteosarcoma
  • Osterix

ASJC Scopus subject areas

  • Oncology

Cite this

Davis, L., Jeng, S., Svalina, M. N., Huang, E., Pittsenbarger, J., Cantor, E. L., ... Keller, C. (2017). Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species. Oncotarget, 8(44), 76241-76256. https://doi.org/10.18632/oncotarget.19532

Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species. / Davis, Lara; Jeng, Sophia; Svalina, Matthew N.; Huang, Elaine; Pittsenbarger, Janét; Cantor, Emma L.; Berlow, Noah; Seguin, Bernard; Mansoor, Atiya; McWeeney, Shannon; Keller, Charles.

In: Oncotarget, Vol. 8, No. 44, 2017, p. 76241-76256.

Research output: Contribution to journalArticle

Davis, L, Jeng, S, Svalina, MN, Huang, E, Pittsenbarger, J, Cantor, EL, Berlow, N, Seguin, B, Mansoor, A, McWeeney, S & Keller, C 2017, 'Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species', Oncotarget, vol. 8, no. 44, pp. 76241-76256. https://doi.org/10.18632/oncotarget.19532
Davis, Lara ; Jeng, Sophia ; Svalina, Matthew N. ; Huang, Elaine ; Pittsenbarger, Janét ; Cantor, Emma L. ; Berlow, Noah ; Seguin, Bernard ; Mansoor, Atiya ; McWeeney, Shannon ; Keller, Charles. / Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species. In: Oncotarget. 2017 ; Vol. 8, No. 44. pp. 76241-76256.
@article{ab6c56e3239041bfb3186cb94d0e6fa7,
title = "Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species",
abstract = "In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell cycle or immune) may prove more successful than targeting specific kinase or growth factor signaling pathways. Here, we establish a comparative oncology approach characterizing the most lethal osteosarcomas identified in a biorepository of tumors from three different species: human, mouse and canine. We describe the development of a genetically-engineered mouse model of osteosarcoma, establishment of primary cell cultures from fatal human tumors, and a biorepository of osteosarcoma surgical specimens from pet dogs. We analyzed the DNA mutations, differential RNA expression and in vitro drug sensitivity from two phenotypically-distinct cohorts: tumors with a highly aggressive biology resulting in death from rapidly progressive, refractory metastatic disease, and tumors with a non-aggressive, curable phenotype. We identified ARK5 (AMPK-Related Protein Kinase 5, also referred to as NUAK Family Kinase 1) as a novel metabolic target present in all species, and independent analyses confirmed glucose metabolism as the most significantly aberrant cellular signaling pathway in a model system for highly metastatic tumors. Pathway integration analysis identified Polo Like Kinase 1 (PLK1)-mediated checkpoint adaptation as critical to the survival of a distinctly aggressive osteosarcoma. The tumor-associated macrophage cytokine CCL18 (C-C Motif Chemokine Ligand 18) was significantly over-expressed in aggressive human osteosarcomas, and a clustering of mutations in the BAGE (B Melanoma Antigen) tumor antigen gene family was found. The theme of these features of high risk osteosarcoma is checkpoint adaptations, which may prove both prognostic and targetable.",
keywords = "Checkpoint adaptation, Comparative oncology, Metastases, Osteosarcoma, Osterix",
author = "Lara Davis and Sophia Jeng and Svalina, {Matthew N.} and Elaine Huang and Jan{\'e}t Pittsenbarger and Cantor, {Emma L.} and Noah Berlow and Bernard Seguin and Atiya Mansoor and Shannon McWeeney and Charles Keller",
year = "2017",
doi = "10.18632/oncotarget.19532",
language = "English (US)",
volume = "8",
pages = "76241--76256",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "44",

}

TY - JOUR

T1 - Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species

AU - Davis, Lara

AU - Jeng, Sophia

AU - Svalina, Matthew N.

AU - Huang, Elaine

AU - Pittsenbarger, Janét

AU - Cantor, Emma L.

AU - Berlow, Noah

AU - Seguin, Bernard

AU - Mansoor, Atiya

AU - McWeeney, Shannon

AU - Keller, Charles

PY - 2017

Y1 - 2017

N2 - In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell cycle or immune) may prove more successful than targeting specific kinase or growth factor signaling pathways. Here, we establish a comparative oncology approach characterizing the most lethal osteosarcomas identified in a biorepository of tumors from three different species: human, mouse and canine. We describe the development of a genetically-engineered mouse model of osteosarcoma, establishment of primary cell cultures from fatal human tumors, and a biorepository of osteosarcoma surgical specimens from pet dogs. We analyzed the DNA mutations, differential RNA expression and in vitro drug sensitivity from two phenotypically-distinct cohorts: tumors with a highly aggressive biology resulting in death from rapidly progressive, refractory metastatic disease, and tumors with a non-aggressive, curable phenotype. We identified ARK5 (AMPK-Related Protein Kinase 5, also referred to as NUAK Family Kinase 1) as a novel metabolic target present in all species, and independent analyses confirmed glucose metabolism as the most significantly aberrant cellular signaling pathway in a model system for highly metastatic tumors. Pathway integration analysis identified Polo Like Kinase 1 (PLK1)-mediated checkpoint adaptation as critical to the survival of a distinctly aggressive osteosarcoma. The tumor-associated macrophage cytokine CCL18 (C-C Motif Chemokine Ligand 18) was significantly over-expressed in aggressive human osteosarcomas, and a clustering of mutations in the BAGE (B Melanoma Antigen) tumor antigen gene family was found. The theme of these features of high risk osteosarcoma is checkpoint adaptations, which may prove both prognostic and targetable.

AB - In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell cycle or immune) may prove more successful than targeting specific kinase or growth factor signaling pathways. Here, we establish a comparative oncology approach characterizing the most lethal osteosarcomas identified in a biorepository of tumors from three different species: human, mouse and canine. We describe the development of a genetically-engineered mouse model of osteosarcoma, establishment of primary cell cultures from fatal human tumors, and a biorepository of osteosarcoma surgical specimens from pet dogs. We analyzed the DNA mutations, differential RNA expression and in vitro drug sensitivity from two phenotypically-distinct cohorts: tumors with a highly aggressive biology resulting in death from rapidly progressive, refractory metastatic disease, and tumors with a non-aggressive, curable phenotype. We identified ARK5 (AMPK-Related Protein Kinase 5, also referred to as NUAK Family Kinase 1) as a novel metabolic target present in all species, and independent analyses confirmed glucose metabolism as the most significantly aberrant cellular signaling pathway in a model system for highly metastatic tumors. Pathway integration analysis identified Polo Like Kinase 1 (PLK1)-mediated checkpoint adaptation as critical to the survival of a distinctly aggressive osteosarcoma. The tumor-associated macrophage cytokine CCL18 (C-C Motif Chemokine Ligand 18) was significantly over-expressed in aggressive human osteosarcomas, and a clustering of mutations in the BAGE (B Melanoma Antigen) tumor antigen gene family was found. The theme of these features of high risk osteosarcoma is checkpoint adaptations, which may prove both prognostic and targetable.

KW - Checkpoint adaptation

KW - Comparative oncology

KW - Metastases

KW - Osteosarcoma

KW - Osterix

UR - http://www.scopus.com/inward/record.url?scp=85030327544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030327544&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19532

DO - 10.18632/oncotarget.19532

M3 - Article

AN - SCOPUS:85030327544

VL - 8

SP - 76241

EP - 76256

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 44

ER -